Department and Institute of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Institute of Virology, Technical University of Munich / Helmholtz Zentrum München, 81675, Munich, Germany.
Sci Rep. 2017 Oct 5;7(1):12715. doi: 10.1038/s41598-017-13082-z.
Previous studies identified APOBEC deaminases as enzymes targeting hepatitis B virus (HBV) DNA in the nucleus thus affecting its persistence. Interferon (IFN)-α treated chimpanzees and hepatitis C patients showed elevated APOBEC expression. We thus hypothesized that the responses to IFN-α treatment of chronic hepatitis B (CHB) patients is influenced by IFN-induced base excision repair (BER). CHB-treatment naïve patients, patients treated with PEGylated IFN-α, and patients with sequential treatment of Entecavior and PEGylated IFN-α were recruited. Blood and liver biopsy samples were collected before treatment and at treatment endpoint. BER genes were assessed by quantitative RT-PCR. BER gene expression levels and IFN treatment responses were correlated in patient liver biopsies. APOBEC3A, -B, -C, -D/E, and-G mRNA levels were up-regulated in IFN-treated patients. APOBEC3A expression was significantly higher in IFN-responders than in non-responders. BER genes NEIL3 was down-regulated in IFN-treated patients. APOBEC3 and BER gene expression at treatment endpoints partially correlated with the corresponding absolute DNA level or degree of HBsAg and HBV DNA decline. Our study suggests that the expression of APOBEC3A positively correlates with IFN-treatment responses in CHB patients, while NEIL3 shows negative correlation. These genes may involve to IFN mediated viral suppression and serve as biomarkers for CHB disease management.
先前的研究表明 APOBEC 脱氨酶是作用于细胞核内乙型肝炎病毒 (HBV) DNA 的酶,从而影响其持续性。干扰素 (IFN)-α 治疗的黑猩猩和丙型肝炎患者表现出 APOBEC 表达升高。因此,我们假设慢性乙型肝炎 (CHB) 患者对 IFN-α 治疗的反应受 IFN 诱导的碱基切除修复 (BER) 影响。招募了 CHB 治疗初治患者、接受聚乙二醇化 IFN-α 治疗的患者和恩替卡韦和聚乙二醇化 IFN-α 序贯治疗的患者。在治疗前和治疗终点采集血液和肝活检样本。通过定量 RT-PCR 评估 BER 基因。在患者肝活检中,BER 基因表达水平与 IFN 治疗反应相关。IFN 治疗患者的 APOBEC3A、-B、-C、-D/E 和 -G mRNA 水平上调。IFN 应答者的 APOBEC3A 表达明显高于无应答者。IFN 治疗患者的 BER 基因 NEIL3 下调。治疗终点时的 APOBEC3 和 BER 基因表达与相应的绝对 DNA 水平或 HBsAg 和 HBV DNA 下降程度部分相关。我们的研究表明,APOBEC3A 的表达与 CHB 患者 IFN 治疗反应呈正相关,而 NEIL3 则呈负相关。这些基因可能参与 IFN 介导的病毒抑制,并可作为 CHB 疾病管理的生物标志物。